The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic ...
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
3d
AstraZeneca (LON:AZN) has had a rough month with its share price down 9.1%. But if you pay close attention, you ...
The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...
AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
Check the time stamp on this data. Updated AI-Generated Signals for Astrazeneca Plc (AZN) available here: AZN.
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback